FORM 4
[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response...
0.5                       
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

SHAULSON JOSEPH H
2. Issuer Name and Ticker or Trading Symbol

YIELD10 BIOSCIENCE, INC. [ YTEN ]
5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

__X__ Director                    _____ 10% Owner
_____ Officer (give title below)    _____ Other (specify below)
(Last)          (First)          (Middle)

C/O YIELD10 BIOSCIENCE, INC., 19 PRESIDENTIAL WAY
3. Date of Earliest Transaction (MM/DD/YYYY)

9/30/2019
(Street)

WOBURN, MA 01801
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
6. Individual or Joint/Group Filing (Check Applicable Line)

_X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (right to buy)  $0.5  9/30/2019    A     16297 (1)     9/30/2019  9/30/2029  Common Stock  16297  $0.46  16297  D   

Explanation of Responses:
(1)  These options were issued to the Reporting Person pursuant to the Issuer's Director Compensation Policy in lieu of $7,500 of cash compensation for services rendered to the Issuer as a member of its Board of Directors and/or a committee thereof during the third quarter of 2019.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
SHAULSON JOSEPH H
C/O YIELD10 BIOSCIENCE, INC.
19 PRESIDENTIAL WAY
WOBURN, MA 01801
X



Signatures
/s/ Megan N. Gates, attorney-in-fact 10/2/2019
**Signature of Reporting Person Date


Yield10 Bioscience (NASDAQ:YTEN)
Historical Stock Chart
From Apr 2024 to May 2024 Click Here for more Yield10 Bioscience Charts.
Yield10 Bioscience (NASDAQ:YTEN)
Historical Stock Chart
From May 2023 to May 2024 Click Here for more Yield10 Bioscience Charts.

Yield10 Bioscience, Inc. News

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
Yield10 Bioscience Announces 1-for-24 Reverse Stock Split
Wednesday 1 May 2024 (2 days ago) • GlobeNewswire Inc.
Yield10 Bioscience Announces Fourth Quarter and Full Year 2023 Financial Results
Tuesday 2 April 2024 (1 month ago) • GlobeNewswire Inc.
Yield10 Bioscience to Announce Fourth Quarter and Full Year 2023 Financial Results and Host a Conference Call on Monday, April 1, 2024
Friday 29 March 2024 (1 month ago) • GlobeNewswire Inc.
Yield10 Bioscience Announces that the Plant Biosafety Office of the Canadian Food Inspection Agency has Cleared Genome-edited E3902 Camelina for Planting in Canada
Tuesday 26 March 2024 (1 month ago) • GlobeNewswire Inc.
USDA-APHIS Determines that Yield10 Bioscience’s Omega-3 Camelina Varieties May Be Planted and Bred in the United States
Thursday 21 March 2024 (1 month ago) • GlobeNewswire Inc.
Yield10 Bioscience Reports that Proprietary Varieties of Winter Camelina Show Tolerance to Commonly Used Herbicides in First Field Tests
Friday 1 March 2024 (2 months ago) • GlobeNewswire Inc.
Form 8-K - Current report
Tuesday 27 February 2024 (2 months ago) • Edgar (US Regulatory)
Form 4 - Statement of changes in beneficial ownership of securities
Wednesday 21 February 2024 (2 months ago) • Edgar (US Regulatory)
Form 4 - Statement of changes in beneficial ownership of securities
Saturday 17 February 2024 (3 months ago) • Edgar (US Regulatory)
Form 4 - Statement of changes in beneficial ownership of securities
Saturday 17 February 2024 (3 months ago) • Edgar (US Regulatory)
Form 4 - Statement of changes in beneficial ownership of securities
Saturday 17 February 2024 (3 months ago) • Edgar (US Regulatory)
Form 8-K - Current report
Saturday 17 February 2024 (3 months ago) • Edgar (US Regulatory)